All In Biotech

Drug Trial Radar · NCT06447025

An Open-Label Study of CTI-1601 in Subjects With Friedreich's Ataxia

An Open-Label Extension Study to Assess the Long-Term Safety, Efficacy, Pharmacodynamics, Pharmacokinetics, and Tolerability of Subcutaneous CTI-1601 in Subjects With Friedreich's Ataxia

Last checked: Nov 19, 2026Latest source record: Oct 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

85

Planned (sponsor's estimate)

Start

Jan 25, 2024

Primary completion

Jan 2027

Study completion Jan 2027

Sponsor

Lead sponsor
Larimar Therapeutics, Inc.Industry
Sponsor type
Industry
First posted
Jun 6, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 2 years, up to 60 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

An open label study designed to evaluate the safety, PK, PD, and clinical effects of long-term daily administration of CTI-1601 enrolling adolescent and adult patients with FRDA who have participated in a prior clinical study of CTI-1601 as well as children (age 2 years and older), adolescents and adults with FRDA who have not participated in a prior clinical study of CTI-1601.

Conditions

  • Friedreich Ataxia

Interventions

  • CTI-1601Drug

    CTI-1601 is a recombinant fusion protein and is intended to deliver human frataxin, the protein deficient in patients with Friedreich's ataxia

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of subjects with treatment-emergent adverse events (TEAEs) by System Organ Class (SOC), Preferred Term (PT) and Maximum SeverityTime frame: Up to 24 months
  2. Change from baseline in electrocardiogram (ECG) parameters including, but not limited to, HR, RR interval, PR interval, QRS duration, QT interval, and QTcF intervalTime frame: Up to 24 months
  3. Change from baseline in left ventricular ejection fraction (LVEF)Time frame: Up to 24 months
  4. Change from baseline in left ventricular end-diastolic volume (LVEDV)Time frame: Up to 24 months
  5. Number of subjects with any suicidal ideation or behavior (Categories 1-10) of the Columbia Suicide Severity Rating Scale (C-SSRS)Time frame: Up to 24 months
  6. Change from baseline at each collection timepoint in tissue frataxin concentrations normalized to total protein observed in buccal cells collected from cheek swabs and skin cells collected from skin punch biopsiesTime frame: Up to 24 months
  7. Change from baseline in motor function as assessed by 9-hole peg test (9-HPT)Time frame: Up to 24 months
  8. Change from baseline in motor function as assessed by the timed 25-foot walk test (T25-FW)Time frame: Up to 24 months
  9. Change from baseline in neurologic function as assessed by the modified Friedreich's Ataxia Rating Scale (mFARS) total scoreTime frame: Up to 24 months
  10. Change from baseline in neurologic function as assessed by the upright stability subscale examination of the mFARSTime frame: Through study completion, up to 24 months
  11. Change in activities of daily living (ADLs) as assessed by the Friedreich's Ataxia Rating Scale Activities of Daily Living (FARS_ADL)Time frame: Up to 24 months
  12. Change from baseline in total fatigue score and all the subscale scores as assessed by the Fatigue Impact Scale (MFIS)Time frame: Up to 24 months
  13. Change from baseline in the assessment of disease as assessed by the Functional Staging for AtaxiaTime frame: Up to 24 months
  14. Overall impression of change as assessed by the patient using the Patient Global Impression of Change (PGI-C) ScaleTime frame: Up to 24 months
  15. Overall impression of change assessed by a clinician using the Clinical Global Impression of Change (CGI-C)Time frame: Up to 24 months
  16. Area under the concentration-time curve for the dosing interval (AUC0-tau)Time frame: Days 1, 30, 60, 90: pre-dose, 5, 15, 30 minutes after the dose, and 1, 2, 4, 6, 8 hours after the dose; Day 180: pre-dose and 5, 15 minutes after the dose; Days 270, 360, Q3M thereafter: pre-dose; through study completion, up to 24 months
  17. Area under the concentration-time curve from time 0 to the time of last quantifiable concentration (AUC0-t)Time frame: Days 1, 30, 60, 90: pre-dose, 5, 15, 30 minutes after the dose, and 1, 2, 4, 6, 8 hours after the dose; Day 180: pre-dose and 5, 15 minutes after the dose; Days 270, 360, Q3M thereafter: pre-dose; through study completion, up to 24 months
  18. Mean maximum observed concentration (Cmax)Time frame: Days 1, 30, 60, 90: pre-dose, 5, 15, 30 minutes after the dose, and 1, 2, 4, 6, 8 hours after the dose; Day 180: pre-dose and 5, 15 minutes after the dose; Days 270, 360, Q3M thereafter: pre-dose; through study completion, up to 24 months
  19. Mean time of maximum observed concentration (Tmax)Time frame: Days 1, 30, 60, 90: pre-dose, 5, 15, 30 minutes after the dose, and 1, 2, 4, 6, 8 hours after the dose; Day 180: pre-dose and 5, 15 minutes after the dose; Days 270, 360, Q3M thereafter: pre-dose; through study completion, up to 24 months
  20. Concentration reached immediately before the next dose is administered (Ctrough)Time frame: Days 1, 30, 60, 90: pre-dose, 5, 15, 30 minutes after the dose, and 1, 2, 4, 6, 8 hours after the dose; Day 180: pre-dose and 5, 15 minutes after the dose; Days 270, 360, Q3M thereafter: pre-dose; through study completion, up to 24 months

Locations

10 sites in 1 country. Site status is shown where the registry gives one.

  • University of California Los Angeles

    Los Angeles, California · Active not recruiting

  • University of California, San Franciso Medical Center

    San Francisco, California · Recruiting

  • Fixel Institute for Neurological Disease, University of Florida Health

    Gainesville, Florida · Active not recruiting

  • Morsani Center for Advanced Health Care, University of South Florida Health

    Tampa, Florida · Recruiting

  • University of Iowa Hospitals & Clinics

    Iowa City, Iowa · Recruiting

  • Uncommon Cures

    Chevy Chase, Maryland · Recruiting

  • Clinilabs Drug Development, Corp.

    Eatontown, New Jersey · Recruiting

  • Ohio State University Wexner Medical Center

    Columbus, Ohio · Active not recruiting

  • Children's Hospital of Philadelphia

    Philadelphia, Pennsylvania · Recruiting

  • ICON

    Salt Lake City, Utah · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.